James Lee, MD
Ophthalmology · Colorado Springs, CONPI 1396772372
Payments from drug & device makers
Across 443 payments — averaging $1018.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$299K
- AbbVie$147K
- Alcon$4K
- Novartis$381
- Rxsight Inc$358
- Johnson & Johnson Surgical Vision, Inc.$212
- plus $834 from 20 others
What the payments were for
- Consulting fees$9,25634%
- Speaking & faculty fees$1,3005%
- Food & beverage$8,86833%
- Education$280%
- Gifts$720%
- Other$7,47528%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 127 | $299,129 |
| AbbVie(2 entities) | 115 | $146,798 |
| Alcon | 137 | $3,598 |
| Novartis | 22 | $381 |
| Rxsight Inc | 5 | $358 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $212 |
| Eyepoint US, Inc. | 1 | $158 |
| Oyster Point Pharma, Inc. | 4 | $90 |
| Vantage Technology LLC | 2 | $81 |
| Sight Sciences, Inc. | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $61 |
| Ocular Therapeutix, Inc. | 3 | $45 |
| Genentech USA, Inc. | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Biotissue Holdings Inc. | 2 | $31 |
| Nova Eye, Inc. | 1 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Optos, Inc. | 1 | $19 |
| Ivantis, Inc | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Harrow Eye, LLC | 1 | $13 |
| NEW World Medical,inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$6,862
- DURYSTA$3,508
- XEN$943
- AcrySof$214
- YUTIQ$158
- Photrexa$135
- Rocklatan$134
- CE-marked KXLA system$124
- INTRALASE FS FEMTOSEC LASER$120
- Clareon$118
- Hydrus Microstent$118
- AcrySof IQ PanOptix UV IOL$115
- AcrySof IQ VIVITY IOL$113
- Centurion$109
- RXSIGHT CONTACT LENS$108
- RXSIGHT INJECTOR CARTRIDGE$108
- RXSIGHT INJECTOR HANDPIECE$108
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$108
- LIGHT ADJUSTABLE LENS (LAL)$108
How this compares
$451,309 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 42 | $52,026 |
| XiidraLifitegrast | 29 | $33,218 |
| LumiganBimatoprost | 64 | $30,866 |
| Prednisolone Acetate | 470 | $23,380 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $11,406 |
| CequaCyclosporine | 13 | $8,659 |
| Ketorolac Tromethamine | 389 | $8,450 |
| MoxifloxacinMoxifloxacin Hcl | 354 | $8,434 |
| Cyclosporine | 14 | $6,812 |
| Latanoprost | 524 | $6,074 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $6,048 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $4,996 |
| Travoprost | 19 | $3,827 |
| Gatifloxacin | 72 | $3,160 |
| TobradexTobramycin/Dexamethasone | 11 | $2,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $146,798 | $94,298136 claims |
| Bausch & Lomb Americas Inc.Xiidra | $23 | $33,21829 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $41 | $8,65913 claims |
| AlconSimbrinza | $3,598 | $4,99625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Colorado Springs
- Ryan RichColorado Springs$2.1M
- James BurdenColorado Springs$276K
- Steven DeweyColorado Springs$246K
- David DavisColorado Springs$220K
- Scott SmetanaColorado Springs$57K
- Charles McMahonColorado Springs$47K
- Erik AndersonColorado Springs$19K
- Matthew ChangColorado Springs$10K
- Narine ViruniColorado Springs$6K
- Jason NobleColorado Springs$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.